Chinese Medical Sciences Journal ›› 2023, Vol. 38 ›› Issue (1): 49-56.doi: 10.24920/004137

• Review • Previous Articles     Next Articles

Advances in Medical Treatment of Primary Aldosteronism

Ying-Jie Li, Zhi-Gang Ji, Jin Wen*()   

  1. Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
  • Received:2022-07-01 Accepted:2022-09-23 Published:2023-03-31 Online:2023-01-16
  • Contact: Jin Wen E-mail:wjpumch@163.com.

Primary aldosteronism (PA) is the most common form of secondary hypertension, with its main manifestations including hypertension and hypokalemia. Early identification of PA is extremely important as PA patients can easily develop cardiovascular complications such as atrial fibrillation, stroke, and myocardial infarction. The past decade has witnessed the rapid advances in the genetics of PA, which has shed new light on PA treatment. While surgery is the first choice for unilateral diseases, bilateral lesions can be treated with mineralocorticoid receptor antagonists (MRAs). The next-generation non-steroidal MRAs are under investigations. New medications including calcium channel blockers, macrophage antibiotics, and aldosterone synthase inhibitors have provided a new perspective for the medical treatment of PA.

Key words: primary aldosteronism, mineralocorticoid receptor antagonists, calcium channel blockers, macrolide antibiotics, aldosterone synthase inhibitors

Copyright © 2021 Chinese Academy of Medical Sciences.  京公安备110402430088  京ICP备06002729号-1  Powered by Magtech.

Supervised by National Health Commission of the People's Republic of China

9 Dongdan Santiao, Dongcheng district, Beijing, 100730 China

Tel: 86-10-65105897  Fax:86-10-65133074 

E-mail: cmsj@cams.cn  www.cmsj.cams.cn

Copyright © 2018 Chinese Academy of Medical Sciences

All right reserved.

京公安备110402430088  京ICP备06002729号-1